As part of the FGF23-Klotho system, α-Klotho is an interesting new biomarker in kidney disease, cardiovascular disease, and possibly associated with mortality. 1 Most studies have performed α-Klotho measurements in serum or plasma. As α-Klotho is primarily expressed in renal epithelial tissue, recently various papers have been published reporting α-Klotho concentrations in urine as well. [2] [3] [4] Although α-Klotho in serum is quite stable (see ref. 5 and own unpublished results), this is not necessarily the same for urine, as urine is a totally different matrix with a high variation, e.g., in pH and ion content. The kit insert refers to temperaturedependent instability of α-Klotho in urine and sensitivity to freeze-thaw cycles (IBL α-Klotho kit insert, version 1.4) . In this study, we investigated the stability of α-Klotho in urine.
RESULTS
Results showed that α-Klotho concentrations in urine can best be measured immediately in fresh catheter urine; after 3 h of incubation at 37°C, concentrations decreased on an average of 82% with wide variability (see Figure 1 ). Addition of a protease inhibitor or 0.1% albumin to freshly voided urine prevented the decrease in α-Klotho urine concentrations. However, this effect is negated after freezing (see Figure 2) .
Upon freezing at − 20°C in all subjects, α-Klotho levels declined at least 50% (average decline 82%) compared with the fresh voided urine. Upon freezing the urine at − 80°C, in two subjects the α-Klotho concentration remained the same; however, on average the α-Klotho concentration decreased by 45% (P = 0.015). An additional freeze-thaw cycle even further decreased the α-Klotho concentrations, both in samples stored at − 80 and at − 20°C. All results are shown in Figure 3 .
DISCUSSION
From these results, we conclude that the protein α-Klotho is highly unstable or the α-Klotho molecule escapes immunochemical detection in urine upon storage at a variety of conditions. The optimal measurement of α-Klotho urine concentrations with the current techniques is in fresh catheter urine. However, this is not feasible for patients in most situations. The effect of urine residing in the bladder at 37°C for a few hours before voiding, similar to freezing and thawing, makes measurements unreliable. We did not reveal the nature of the process or processes that lead to this remarkable decrease in the concentration of detectable α-Klotho immunoreactivity. Freeze-thaw is a possible mechanism for the loss of immunoreactivity. However, we believe that our experiments also demonstrate that other mechanisms must be involved, because even in the absence of freeze-thaw α-Klotho immunoreactivity declines steeply. It is conceivable that loss of glycosylation, conformational changes, or simply degradation in fragments that are not detected with the assay used have a role. This process can at least partially be prevented by adding protease inhibitors or albumin to the urine directly after the collection.
Apart from the evident instability of α-Klotho in urine specimens, the variation between the individual specimens is 
worth mentioning, and it should be taken into account. Storage at − 20°C appears to be harmful to the immunoreactivity in all specimens, whereas storage at − 80°C appears to offer at least some protection to degradation in some individuals ( Figure 3 and see Supplementary Figure S1 online). None of the previously published studies measuring urinary α-Klotho 2-4 mentioned how the degradation of α-Klotho in urine was prevented, and it should therefore be interpreted with caution. The use of current techniques to measure α-Klotho in urine in clinical or research setting should be avoided, because it can easily induce flawed conclusions. The development of more valid methods to measure α-Klotho, especially in the urine, is warranted. In addition, before application in clinical or research settings, formal validation studies should be performed.
MATERIALS AND METHODS
We used fresh voided urine samples of 10 subjects (all healthcare coworkers) who gave informed consent: 2 male and 8 female, with an age range of 21-60 years. All subjects collected a portion of urine between 0745 and 0955 hours. The urine of every subject was divided over seven aliquots in polypropylene tubes with screw caps. In one aliquot, α-Klotho concentration was measured immediately after collection. Samples were pipetted in the 96-well plate at 1100 hours on the day of collection. The six other aliquots underwent the following procedures: one aliquot was immediately put in the freezer (−80°C), one aliquot was immediately put in the freezer (−80°C) and then underwent one additional freeze-thaw cycle, one aliquot was immediately put in the freezer (−20°C), one aliquot was immediately put in the freezer (−20°C) and then underwent one additional freeze-thaw cycle, one aliquot was placed for 6 h at room temperature before being put in the freezer (−80°C), and one aliquot was placed for 24 h on a table at room temperature before being put in the freezer (−80°C) before analysis took place. The urine was placed in the freezer in polypropylene tubes with screw caps just before 1100 hours. The urine samples were thawed one week later by placing them on the table at room temperature, and α-Klotho was immediately measured after being mixed and centrifuged. The aliquots that underwent another freeze-thaw cycle were put back into the freezer after being thawed and were thawed again after another week. Then, these aliquots were mixed and centrifuged and analyzed immediately. Two out of 10 of the freshly voided urine samples were below the limit of detection, and the urine aliquots of these subjects were not used for further analysis.
In addition, we drained freshly produced urine from indwelling catheters from five patients admitted to the intensive care unit. These collections were performed after obtaining approval by the local ethics committee. In these samples, we measured α-Klotho concentrations directly and after an incubation of 3 h at 37°C.
Furthermore, we used freshly voided urine samples of five subjects. The urine of every subject was divided over 6 aliquots in polypropylene tubes with screw caps. One aliquot was not treated. To one aliquot, a cocktail of protease inhibitors was immediately added (per 10 ml of urine, one tablet of complete mini EDTAfree (Roche Diagnostics, Mannheim, Germany)). To one aliquot, 0.1% human albumin (Sigma-Aldrich, St Louis, MO, USA) was immediately added. In these three aliquots, α-Klotho was immediately measured. Samples were pipetted in the 96-well plate at 1100 hours on the day of collection. The other three aliquots were treated in the same way; however, they were immediately put in the freezer (−20°C). These urine samples were thawed 1 week later by placing them on the table at room temperature and then they were immediately analyzed for α-Klotho after being mixed and centrifuged.
The α-Klotho immunoassay (IBL international GmbH, Hamburg, Germany) 6 was performed as described by the manufacturer, with minor adjustments. A longer incubation (overnight) and a larger sample volume (200 μl) were used, in order to be able to measure the lower α-Klotho concentrations in urine compared with serum. Intra-assay variation in urine samples was 4.1 and 7.9% at a level of 10 and 242 pg/ml, respectively, which is comparable to the reported performance of this assay in serum. 6 For all α-Klotho measurements, we used the same lot number of reagents. Controls gave comparable results.
Conditions were compared using either a paired T-test or an analysis of variance with repeated measurements. P-values ⩽ 0.05 were considered to reflect statistical significance.
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